| Year |
Citation |
Score |
| 2020 |
Itkonen HM, Poulose N, Steele RE, Martin SES, Levine ZG, Duveau DY, Carelli R, Singh R, Urbanucci A, Loda M, Thomas CJ, Mills IG, Walker S. Inhibition of O-GlcNAc transferase renders prostate cancer cells dependent on CDK9. Molecular Cancer Research : McR. PMID 32611550 DOI: 10.1158/1541-7786.Mcr-20-0339 |
0.358 |
|
| 2020 |
Harrington BS, Ozaki MK, Caminear MW, Hernandez LF, Jordan E, Kalinowski NJ, Goldlust IS, Guha R, Ferrer M, Thomas C, Shetty J, Tran B, Wong N, House CD, Annunziata CM. Drugs Targeting Tumor-Initiating Cells Prolong Survival in a Post-Surgery, Post-Chemotherapy Ovarian Cancer Relapse Model. Cancers. 12. PMID 32575908 DOI: 10.3390/Cancers12061645 |
0.342 |
|
| 2020 |
Issaq SH, Mendoza A, Kidner R, Rosales TI, Duveau DY, Heske CM, Rohde JM, Boxer MB, Thomas CJ, DeBerardinis RJ, Helman LJ. EWS-FLI1-regulated serine synthesis and exogenous serine are necessary for Ewing sarcoma cellular proliferation and tumor growth. Molecular Cancer Therapeutics. PMID 32371575 DOI: 10.1158/1535-7163.Mct-19-0748 |
0.372 |
|
| 2020 |
Wei D, Yang Y, Ricketts CJ, Vocke CD, Ball M, Sourbier C, Wangsa D, Wangsa D, Guha R, Zhang X, Wilson K, Chen L, Meltzer PS, Ried T, Thomas CJ, et al. Novel renal medullary carcinoma cell lines, UOK353 and UOK360, provide preclinical tools to identify new therapeutic treatments. Genes, Chromosomes & Cancer. PMID 32259323 DOI: 10.1002/Gcc.22847 |
0.339 |
|
| 2020 |
Burgess TL, Amason JD, Rubin JS, Duveau DY, Lamy L, Roberts DD, Farrell CL, Inglese J, Thomas CJ, Miller TW. A homogeneous SIRPα-CD47 cell-based, ligand-binding assay: Utility for small molecule drug development in immuno-oncology. Plos One. 15: e0226661. PMID 32240171 DOI: 10.1371/Journal.Pone.0226661 |
0.338 |
|
| 2020 |
Jones LM, Melgar K, Bolanos L, Hueneman K, Walker MM, Jiang JK, Wilson KM, Zhang X, Shen J, Jiang F, Sutter P, Wang A, Xu X, Tawa GJ, Hoyt SB, ... ... Thomas CJ, et al. Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. The Journal of Clinical Investigation. PMID 32149729 DOI: 10.1172/Jci127907 |
0.323 |
|
| 2020 |
Yohe ME, Gryder BE, Chou H, Song YK, Zhang X, Butcher D, Isanogle KA, Robinson CM, Luo X, Chen J, Edmondson EJ, Difilippantionio S, Thomas CJ, Khan J. Abstract B17: MEK inhibition induces myogenic differentiation in RAS-driven rhabdomyosarcoma Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Ras18-B17 |
0.325 |
|
| 2020 |
Bondesson AJ, Miyaki A, Shin S, Ceribelli M, Thomas CJ, Gujral TS. Abstract B32: High-throughput chemical screening reveals YAP-mediated alterations in drug sensitivities Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Hippo19-B32 |
0.409 |
|
| 2020 |
Ceribelli M, Morris P, Duveau D, Tosto FA, Hoyt S, Thomas CJ. Abstract B06: Development of selective LATS1/LATS2 inhibitors for the pharmacologic modulation of the Hippo signaling pathway Molecular Cancer Research. 18. DOI: 10.1158/1557-3125.Hippo19-B06 |
0.38 |
|
| 2020 |
Issaq S, Mendoza A, Rosales T, Heske C, Thomas C, DeBerardinis R, Helman L. Abstract 5714: Targeting serine metabolism impairs tumor growth in preclinical models of Ewing sarcoma Cancer Research. 80: 5714-5714. DOI: 10.1158/1538-7445.Am2020-5714 |
0.366 |
|
| 2020 |
Sayers CM, Carter MB, Lei H, Shema S, Zhang X, Wilson K, Chen L, Thomas CJ, Shern JF. Abstract 457: Discovery and characterization of GNF-7 as a preferentially cytotoxic compound for camptothecin-resistant Ewing sarcoma cells Cancer Research. 80: 457-457. DOI: 10.1158/1538-7445.Am2020-457 |
0.393 |
|
| 2020 |
Pahwa R, Dubhashi J, Giri A, Thomas C, Ceribelli M, Jailwala P, Lobanov A, Singh A, Sourbier C, Ricketts CJ, Vocke CD, Yang Y, Linehan WM, Srinivasan R. Abstract 4221: Anti-Tumor activity of the multityrosine kinase inhibitor dasatinib in type 1 papillary renal cell carcinoma Cancer Research. 80: 4221-4221. DOI: 10.1158/1538-7445.Am2020-4221 |
0.38 |
|
| 2019 |
Vian L, Le MT, Gazaniga N, Kieltyka J, Liu C, Pietropaolo G, Dell'Orso S, Brooks SR, Furumoto Y, Thomas CJ, O'Shea JJ, Sciumè G, Gadina M. JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis. Frontiers in Immunology. 10: 2972. PMID 31921209 DOI: 10.3389/Fimmu.2019.02972 |
0.332 |
|
| 2019 |
Lin GL, Wilson KM, Ceribelli M, Stanton BZ, Woo PJ, Kreimer S, Qin EY, Zhang X, Lennon J, Nagaraja S, Morris PJ, Quezada M, Gillespie SM, Duveau DY, Michalowski AM, ... ... Thomas CJ, et al. Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening. Science Translational Medicine. 11. PMID 31748226 DOI: 10.1126/Scitranslmed.Aaw0064 |
0.356 |
|
| 2019 |
Chan K, Robert F, Oertlin C, Kapeller-Libermann D, Avizonis D, Gutierrez J, Handly-Santana A, Doubrovin M, Park J, Schoepfer C, Da Silva B, Yao M, Gorton F, Shi J, Thomas CJ, et al. eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma. Nature Communications. 10: 5151. PMID 31723131 DOI: 10.1038/S41467-019-13086-5 |
0.33 |
|
| 2019 |
Whitehouse AJ, Libardo MDJ, Kasbekar M, Brear PD, Fischer G, Thomas CJ, Barry C, Boshoff HIM, Coyne AG, Abell C. Targeting of fumarate hydratase from Mycobacterium tuberculosis using allosteric inhibitors with a dimeric-binding mode. Journal of Medicinal Chemistry. PMID 31517489 DOI: 10.1021/Acs.Jmedchem.9B01203 |
0.323 |
|
| 2019 |
Melgar K, Walker MM, Jones LM, Bolanos LC, Hueneman K, Wunderlich M, Jiang JK, Wilson KM, Zhang X, Sutter P, Wang A, Xu X, Choi K, Tawa G, Lorimer D, ... ... Thomas CJ, et al. Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science Translational Medicine. 11. PMID 31484791 DOI: 10.1126/scitranslmed.aaw8828 |
0.339 |
|
| 2019 |
Alkhilaiwi F, Paul S, Zhou D, Zhang X, Wang F, Palechor-Ceron N, Wilson K, Guha R, Ferrer M, Grant N, Thomas C, Schlegel R, Yuan H. High-throughput screening identifies candidate drugs for the treatment of recurrent respiratory papillomatosis. Papillomavirus Research (Amsterdam, Netherlands). 100181. PMID 31446060 DOI: 10.1016/J.Pvr.2019.100181 |
0.304 |
|
| 2019 |
Bian Y, Teper Y, Mathews Greiner LA, Aiken TJ, Shukla V, Guha R, Shinn P, Xin HW, Pflicke H, Powers AS, Li D, Jiang JK, Patel P, Rogers S, Aubé J, ... ... Thomas CJ, et al. Target deconvolution of a multikinase inhibitor with anti-metastatic properties identifies TAOK3 as a key contributor to a cancer stem cell-like phenotype. Molecular Cancer Therapeutics. PMID 31395684 DOI: 10.1158/1535-7163.Mct-18-1011 |
0.381 |
|
| 2018 |
Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Fang L, Hynes PG, Alilin AN, Lake R, Abbey YC, Cawley J, Tice CM, Yin J, ... ... Thomas CJ, et al. High-throughput screens identify HSP90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer. Scientific Reports. 8: 17239. PMID 30467317 DOI: 10.1038/S41598-018-35417-0 |
0.391 |
|
| 2018 |
Martin SES, Tan ZW, Itkonen HM, Duveau DY, Paulo JA, Janetzko J, Boutz PL, Törk L, Moss FA, Thomas CJ, Gygi SP, Lazarus MB, Walker S. Structure-Based Evolution of Low Nanomolar O-GlcNAc Transferase Inhibitors. Journal of the American Chemical Society. PMID 30285435 DOI: 10.1021/Jacs.8B07328 |
0.349 |
|
| 2018 |
Yohe ME, Gryder BE, Shern JF, Song YK, Chou HC, Sindiri S, Mendoza A, Patidar R, Zhang X, Guha R, Butcher D, Isanogle KA, Robinson CM, Luo X, Chen JQ, ... ... Thomas CJ, et al. MEK inhibition induces MYOG and remodels super-enhancers in RAS-driven rhabdomyosarcoma. Science Translational Medicine. 10. PMID 29973406 DOI: 10.1126/Scitranslmed.Aan4470 |
0.318 |
|
| 2018 |
Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, Pereira EFR, Albuquerque EX, Thomas CJ, Zarate CA, Gould TD. Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms. Pharmacological Reviews. 70: 621-660. PMID 29945898 DOI: 10.1124/Pr.117.015198 |
0.302 |
|
| 2018 |
Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M, Shaffer AL, Ceribelli M, Wang JQ, Schmitz R, Nakagawa M, Bachy E, Huang DW, Ji Y, Chen L, ... ... Thomas CJ, et al. A multiprotein supercomplex controlling oncogenic signalling in lymphoma. Nature. PMID 29925955 DOI: 10.1038/S41586-018-0290-0 |
0.333 |
|
| 2018 |
Ferrer M, Gosline SJC, Stathis M, Zhang X, Guo X, Guha R, Ryman DA, Wallace MR, Kasch-Semenza L, Hao H, Ingersoll R, Mohr D, Thomas C, Verma S, Guinney J, et al. Pharmacological and genomic profiling of neurofibromatosis type 1 plexiform neurofibroma-derived schwann cells. Scientific Data. 5: 180106. PMID 29893754 DOI: 10.1038/Sdata.2018.106 |
0.309 |
|
| 2018 |
McKinnon T, Venier R, Yohe M, Sindiri S, Gryder BE, Shern JF, Kabaroff L, Dickson B, Schleicher K, Chouinard-Pelletier G, Menezes S, Gupta A, Zhang X, Guha R, Ferrer M, ... Thomas CJ, et al. Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma. Oncogene. PMID 29487419 DOI: 10.1038/S41388-017-0122-Y |
0.394 |
|
| 2018 |
Calabrese DR, Zlotkowski K, Alden S, Hewitt WM, Connelly CM, Wilson RM, Gaikwad S, Chen L, Guha R, Thomas CJ, Mock BA, Schneekloth JS. Characterization of clinically used oral antiseptics as quadruplex-binding ligands. Nucleic Acids Research. PMID 29481610 DOI: 10.1093/Nar/Gky084 |
0.311 |
|
| 2018 |
Jansson KH, Tucker JB, Stahl LE, Simmons JK, Fuller C, Beshiri ML, Agarwal S, Abbey Y, Fang L, Hynes PG, Neil AA, Cawley J, Lake R, Tran C, Tice CM, ... ... Thomas CJ, et al. Abstract B018: A high-throughput screen identifies HSP90 inhibitors as potent therapeutics across multiple clinically representative organoid models of advanced prostate cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Prca2017-B018 |
0.388 |
|
| 2018 |
Romero R, Sayin VI, Shawn DM, Bauer M, Singh SX, LeBoeuf S, Karakousi TR, Ellis DC, Bhutkar A, Sanchez-Rivera F, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, ... Thomas CJ, et al. Abstract A43: Loss of Keap1 promotes KRAS-driven lung cancer and results in genotype-specific vulnerabilities Cancer Research. 78. DOI: 10.1158/1538-7445.Mousemodels17-A43 |
0.305 |
|
| 2018 |
Pahwa R, Giri A, Sourbier C, Thomas C, Linehan WM, Neckers L, Srinivasan R. Abstract 3842: Potent antitumor activity of the HSP90 inhibitor SNX-2112 in type 1 papillary renal cell carcinoma Cancer Research. 78: 3842-3842. DOI: 10.1158/1538-7445.Am2018-3842 |
0.394 |
|
| 2018 |
Ozaki MK, House CD, Mazan-Mamczarz K, Lal-Nag M, Thomas C, Annunziata CM. Abstract 167: Targeting the NF-kappaB pathway with bardoxolone methyl to inhibit ovarian cancer spheroid formation Cancer Research. 78: 167-167. DOI: 10.1158/1538-7445.Am2018-167 |
0.348 |
|
| 2017 |
Venkatesh HS, Tam LT, Woo PJ, Lennon J, Nagaraja S, Gillespie SM, Ni J, Duveau DY, Morris PJ, Zhao JJ, Thomas CJ, Monje M. Targeting neuronal activity-regulated neuroligin-3 dependency in high-grade glioma. Nature. 549: 533-537. PMID 28959975 DOI: 10.1038/Nature24014 |
0.336 |
|
| 2017 |
Heske CM, Davis MI, Baumgart JT, Wilson KM, Gormally MV, Chen L, Zhang X, Ceribelli M, Duveau D, Guha R, Ferrer M, Arnaldez FI, Ji JJ, Tran HL, Zhang Y, ... ... Thomas CJ, et al. Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28899971 DOI: 10.1158/1078-0432.Ccr-17-1121 |
0.369 |
|
| 2017 |
Hassett M, Sternberg A, Riegel B, Thomas CJ, Roepe PD. Heterologous Expression, Purification, and Functional Analysis of Plasmodium falciparum Phosphatidylinositol 3'-Kinase. Biochemistry. PMID 28719180 DOI: 10.1021/Acs.Biochem.7B00416 |
0.342 |
|
| 2017 |
Lionakis MS, Dunleavy K, Roschewski M, Widemann BC, Butman JA, Schmitz R, Yang Y, Cole DE, Melani C, Higham CS, Desai JV, Ceribelli M, Chen L, Thomas CJ, Little RF, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma. Cancer Cell. PMID 28552327 DOI: 10.1016/J.Ccell.2017.04.012 |
0.303 |
|
| 2017 |
Gryder BE, Yohe ME, Chou HC, Zhang X, Marques J, Wachtel M, Schaefer B, Sen N, Song YK, Gualtieri A, Pomella S, Rota R, Cleveland A, Wen X, Sindiri S, ... ... Thomas CJ, et al. PAX3-FOXO1 Establishes Myogenic Super Enhancers and Confers BET Bromodomain Vulnerability. Cancer Discovery. PMID 28446439 DOI: 10.1158/2159-8290.Cd-16-1297 |
0.326 |
|
| 2017 |
Nelson EA, Dyall J, Hoenen T, Barnes AB, Zhou H, Liang JY, Michelotti J, Dewey WH, DeWald LE, Bennett RS, Morris PJ, Guha R, Klumpp-Thomas C, McKnight C, Chen YC, ... ... Thomas C, et al. The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection. Plos Neglected Tropical Diseases. 11: e0005540. PMID 28403145 DOI: 10.1371/Journal.Pntd.0005540 |
0.305 |
|
| 2017 |
Baumgart JT, Heske C, Davis MI, Wilson K, Zhang X, Guha R, Ferrer M, Mendoza A, Thomas CJ, Helman LJ. Abstract 1930: Evaluating the effect of PARP inhibitors in combination with nicotinamide phosphoribosyltransferase inhibitors in Ewing sarcoma Cancer Research. 77: 1930-1930. DOI: 10.1158/1538-7445.Am2017-1930 |
0.309 |
|
| 2016 |
Mathews Griner LA, Zhang X, Guha R, McKnight C, Goldlust IS, Lal-Nag M, Wilson K, Michael S, Titus S, Shinn P, Thomas CJ, Ferrer M. Large-scale pharmacological profiling of 3D tumor models of cancer cells. Cell Death & Disease. 7: e2492. PMID 27906188 DOI: 10.1038/Cddis.2016.360 |
0.347 |
|
| 2016 |
Ceribelli M, Hou ZE, Kelly PN, Huang DW, Wright G, Ganapathi K, Evbuomwan MO, Pittaluga S, Shaffer AL, Marcucci G, Forman SJ, Xiao W, Guha R, Zhang X, Ferrer M, ... ... Thomas CJ, et al. A Druggable TCF4- and BRD4-Dependent Transcriptional Network Sustains Malignancy in Blastic Plasmacytoid Dendritic Cell Neoplasm. Cancer Cell. 30: 764-778. PMID 27846392 DOI: 10.1182/Blood.V128.22.1513.1513 |
0.31 |
|
| 2016 |
Gui DY, Sullivan LB, Luengo A, Hosios AM, Bush LN, Gitego N, Davidson SM, Freinkman E, Thomas CJ, Vander Heiden MG. Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin. Cell Metabolism. PMID 27746050 DOI: 10.1016/J.Cmet.2016.09.006 |
0.335 |
|
| 2016 |
Antignani A, Mathews Griner L, Guha R, Simon N, Pasetto M, Keller J, Huang M, Angelus E, Pastan I, Ferrer M, FitzGerald DJ, Thomas CJ. Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins. Plos One. 11: e0161415. PMID 27556570 DOI: 10.1371/Journal.Pone.0161415 |
0.383 |
|
| 2016 |
Kasbekar M, Fischer G, Mott BT, Yasgar A, Hyvönen M, Boshoff HI, Abell C, Barry CE, Thomas CJ. Selective small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase reveals an allosteric regulatory site. Proceedings of the National Academy of Sciences of the United States of America. PMID 27325754 DOI: 10.1073/Pnas.1600630113 |
0.324 |
|
| 2016 |
Li Y, Bouchlaka MN, Wolff J, Grindle KM, Lu L, Qian S, Zhong X, Pflum N, Jobin P, Kahl BS, Eickhoff JC, Wuerzberger-Davis SM, Miyamoto S, Thomas CJ, Yang DT, et al. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene. PMID 27157620 DOI: 10.1038/Onc.2016.155 |
0.354 |
|
| 2016 |
Guha R, Mathews Griner LA, Keller JM, Zhang X, Fitzgerald D, Antignani A, Pastan I, Thomas CJ, Ferrer M. Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens. Journal of Biomolecular Screening. PMID 27112173 DOI: 10.1177/1087057116644890 |
0.324 |
|
| 2016 |
Ju W, Zhang M, Wilson KM, Petrus MN, Bamford RN, Zhang X, Guha R, Ferrer M, Thomas CJ, Waldmann TA. Augmented efficacy of brentuximab vedotin combined with ruxolitinib and/or Navitoclax in a murine model of human Hodgkin's lymphoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 26811457 DOI: 10.1073/Pnas.1524668113 |
0.351 |
|
| 2016 |
Krane LS, Railkar R, Hsu I, Vocke C, Meltzer PS, Thomas C, Ferrer M, Agarwal PK. High throughput screening to assess urothelial cancer lines and their metastatic derivatives for assessing changes in sensitivity in therapeutics. Journal of Clinical Oncology. 34: 407-407. DOI: 10.1200/Jco.2016.34.2_Suppl.407 |
0.344 |
|
| 2016 |
Heske C, Davis MI, Baumgart JT, Wilson K, Gormally MV, Zhang X, Duveau DY, Guha R, Ferrer M, Mendoza A, Thomas CJ, Helman LJ. Assessing the activity of combining PARP inhibitors (PARPi) and Nicotinamide phosphoribosyltransferase inhibitors (NAMPTi) in Ewing sarcoma (ES). Journal of Clinical Oncology. 34: 11022-11022. DOI: 10.1200/Jco.2016.34.15_Suppl.11022 |
0.32 |
|
| 2016 |
Melgar K, Walker M, Jiang J, Wison K, Choi K, Mulloy JC, Thomas CJ, Starczynowski DT. Molecular Analysis and In Vivo Efficacy Studies on a Novel Chemical-Series of FLT3 Inhibitors in Human FLT3-ITD AML Blood. 128: 36-36. DOI: 10.1182/Blood.V128.22.36.36 |
0.366 |
|
| 2016 |
Antignani A, Mathews-Griner L, Ferrer M, Simon N, Angelus E, Huang M, Pastan I, Thomas C, FitzGerald DJ. Abstract A67: The mTOR inhibitor, everolimus, enhances the cytotoxicity of pseudomonas-based immunotoxins: Mechanistic insights Molecular Cancer Research. 14. DOI: 10.1158/1557-3125.Metca15-A67 |
0.413 |
|
| 2016 |
Gryder BE, Yohe ME, Shern J, Chou H, Song Y, Patidar R, Li S, Sindiri S, Cleveland A, Liao H, Wen X, Zhang X, Mathews-Griner L, Guha R, Shinn P, ... ... Thomas C, et al. Abstract PR16: Targeting the chromatin architecture established by PAX3-FOXO1 in rhabdomyosarcoma Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-Pr16 |
0.354 |
|
| 2016 |
Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Griner LAM, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, ... ... Thomas CJ, et al. Abstract B31: Combined siRNA and small molecule screening identifies Aurora B kinase as an effective target in MYCN-driven neuroblastoma Cancer Research. 76. DOI: 10.1158/1538-7445.Pedca15-B31 |
0.394 |
|
| 2016 |
Aiken T, Bian Y, Teper Y, Griner LM, Guha R, Shinn P, Xin H, Pflicke H, Jiang J, Patel P, Rogers S, Aube J, Ferrer M, Thomas CJ, Rudloff U. Abstract B36: Preclinical development of a multikinase targeting molecule with activity against the cancer stem cell phenotype in pancreatic adenocarcinoma Cancer Research. 76. DOI: 10.1158/1538-7445.Panca16-B36 |
0.301 |
|
| 2016 |
Jansson KH, Simmons JK, Fuller C, Agarwal S, Hynes PG, Fang L, Lake R, Cawley J, Stahl L, Zhang X, Guha R, Thomas C, Kelly K. Abstract LB-281: Elucidating potential therapeutic targets in a model of Pten/Tp53 null prostate cancer using high-throughput screening technology Cancer Research. 76. DOI: 10.1158/1538-7445.Am2016-Lb-281 |
0.368 |
|
| 2016 |
Ali-Rahmani F, Fitzgerald D, Martin S, Patel P, Prunotto M, Ormanoglu P, Thomas C, Pastan I. Abstract 743: Tyrosine kinase discoidin domain receptor-1 (DDR1) regulates cytotoxicity of recombinant immunotoxin for cancer therapy Cancer Research. 76: 743-743. DOI: 10.1158/1538-7445.Am2016-743 |
0.385 |
|
| 2016 |
Railkar R, Nair A, Lewi K, Krane S, Guha R, Ferrer M, Thomas C, Agarwal PK. Abstract 3758: Quantitative high-throughput screening as a tool to identify novel therapies in bladder cancer: lessons from flavopiridol Cancer Research. 76: 3758-3758. DOI: 10.1158/1538-7445.Am2016-3758 |
0.382 |
|
| 2016 |
Gormally M, Marsico G, Rai G, Lowe C, Thomas C, Maloney D, Michael S, Matak-Vincovic D, Jadhav A, Simeonov A, Balasubramanian S. Abstract 3088: Transcription factor as target: Novel small molecule inhibits FOXM1 DNA binding and oncogenic gene products Cancer Research. 76: 3088-3088. DOI: 10.1158/1538-7445.Am2016-3088 |
0.362 |
|
| 2016 |
Goldlust IS, Wilson K, Szabova L, Zhang X, Mathews-Griner L, Vias M, Piskorz A, Stark R, Mendil L, Kasbekar M, Braisted J, Guha R, McKnight C, Shinn P, Michelle-Smith D, ... ... Thomas C, et al. Abstract 278: No cell left behind: Residual ovarian spheroids drive recurrence and are sensitive to the pro-oxidant elesclomol Cancer Research. 76: 278-278. DOI: 10.1158/1538-7445.Am2016-278 |
0.361 |
|
| 2016 |
Roberts DD, Smith A, Sipes JM, Wilson A, Mathews-Griner L, Guha R, Thomas CJ, Ferrer M, Soto-Pantoja DR. Abstract 1352: High-throughput matrix screening reveals synergistic chemotherapeutic combinations with blockade of CD47 to enhance cytotoxicity in breast cancer Cancer Research. 76: 1352-1352. DOI: 10.1158/1538-7445.Am2016-1352 |
0.307 |
|
| 2016 |
Krane L, Railkar R, Hsu I, Sidana A, Hammerich K, Vocke C, Meltzer P, Thomas C, Ferrer M, Agarwal P. Mp61-04 Alterations In Cell Line Sensitivity To Small Molecule Inhibitors Between Urothelial Cancer Lines And Their Metastatic Derivatives The Journal of Urology. 195. DOI: 10.1016/J.Juro.2016.02.878 |
0.305 |
|
| 2015 |
Ali-Rahmani F, FitzGerald DJ, Martin S, Patel P, Prunotto M, Ormanoglu P, Thomas C, Pastan I. Anticancer Effects of Mesothelin-targeted Immunotoxin Therapy are Regulated by Tyrosine Kinase DDR1. Cancer Research. PMID 26719540 DOI: 10.1158/0008-5472.Can-15-2401 |
0.382 |
|
| 2015 |
Bogen D, Wei JS, Azorsa DO, Ormanoglu P, Buehler E, Guha R, Keller JM, Mathews Griner LA, Ferrer M, Song YK, Liao H, Mendoza A, Gryder BE, Sindri S, He J, ... ... Thomas CJ, et al. Aurora B kinase is a potent and selective target in MYCN-driven neuroblastoma. Oncotarget. PMID 26497213 DOI: 10.18632/Oncotarget.6208 |
0.39 |
|
| 2015 |
Mott BT, Eastman RT, Guha R, Sherlach KS, Siriwardana A, Shinn P, McKnight C, Michael S, Lacerda-Queiroz N, Patel PR, Khine P, Sun H, Kasbekar M, Aghdam N, Fontaine SD, ... ... Thomas CJ, et al. High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations. Scientific Reports. 5: 13891. PMID 26403635 DOI: 10.1038/Srep13891 |
0.32 |
|
| 2015 |
Zhang M, Mathews Griner LA, Ju W, Duveau DY, Guha R, Petrus MN, Wen B, Maeda M, Shinn P, Ferrer M, Conlon KD, Bamford RN, O'Shea JJ, Thomas CJ, Waldmann TA. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia. Proceedings of the National Academy of Sciences of the United States of America. 112: 12480-5. PMID 26396258 DOI: 10.1073/Pnas.1516208112 |
0.36 |
|
| 2015 |
Lee JA, Shinn P, Jaken S, Oliver S, Willard FS, Heidler S, Peery RB, Oler J, Chu S, Southall N, Dexheimer TS, Smallwood J, Huang R, Guha R, Jadhav A, ... ... Thomas CJ, et al. Novel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of Assays. Plos One. 10: e0130796. PMID 26177200 DOI: 10.1371/Journal.Pone.0130796 |
0.337 |
|
| 2015 |
Ortiz-Meoz RF, Jiang J, Lazarus MB, Orman M, Janetzko J, Fan C, Duveau DY, Tan ZW, Thomas CJ, Walker S. A small molecule that inhibits OGT activity in cells. Acs Chemical Biology. 10: 1392-7. PMID 25751766 DOI: 10.1021/Acschembio.5B00004 |
0.338 |
|
| 2015 |
Wang S, Chen XA, Hu J, Jiang JK, Li Y, Chan-Salis KY, Gu Y, Chen G, Thomas C, Pugh BF, Wang Y. ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells. Molecular Cancer Therapeutics. 14: 877-88. PMID 25612620 DOI: 10.1158/1535-7163.Mct-14-1093-T |
0.345 |
|
| 2015 |
Lu G, Lomonosova E, Cheng X, Moran EA, Meyers MJ, Le Grice SF, Thomas CJ, Jiang JK, Meck C, Hirsch DR, D'Erasmo MP, Suyabatmaz DM, Murelli RP, Tavis JE. Hydroxylated tropolones inhibit hepatitis B virus replication by blocking viral ribonuclease H activity. Antimicrobial Agents and Chemotherapy. 59: 1070-9. PMID 25451058 DOI: 10.1128/Aac.04617-14 |
0.314 |
|
| 2015 |
Zhang M, Griner LAM, Ju W, Duveau DY, Guha R, Petrus MN, Wen B, Maeda M, Shinn P, Ferrer M, Conlon KD, Bamford RN, O'Shea JJ, Thomas CJ, Waldmann TA. Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia Proceedings of the National Academy of Sciences of the United States of America. 112: 12480-12485. DOI: 10.1186/1742-4690-12-S1-O42 |
0.341 |
|
| 2015 |
Melgar K, Walker M, Jiang J, Wilson K, Mulloy JC, Thomas CJ, Starczynowski DT. Novel Small Molecule FLT3 Inhibitors for the Treatment of FLT3-ITD AML Blood. 126: 3690-3690. DOI: 10.1182/Blood.V126.23.3690.3690 |
0.368 |
|
| 2015 |
Bunch K, Goldlust I, Thomas C, Hernandez L, Guha R, Annunziata C. Abstract LB-254: High-throughput drug matrix screen with SMAC (second mitochondria-derived activator of caspases)-mimetic birinapant in high-grade serous ovarian cancer cell lines identifies synergism Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Lb-254 |
0.38 |
|
| 2015 |
Ali-Rahmani FG, Fitzgerald D, Martin S, Patel P, Thomas C, Pastan I. Abstract 5357: Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) tyrosine kinase enhances cytotoxicity of anti-mesothelin immunotoxin for cancer therapy Cancer Research. 75: 5357-5357. DOI: 10.1158/1538-7445.Am2015-5357 |
0.379 |
|
| 2015 |
Bunch KP, Goldlust IS, Thomas CJ, Annunziata CM. High-throughput matrix screening in ovarian cancer cells identifies synergistic drug combinations with the second mitochondrial-derived activator of caspases (SMAC) mimetic birinapant (TL32711) Gynecologic Oncology. 137: 207-208. DOI: 10.1016/J.Ygyno.2015.01.522 |
0.318 |
|
| 2014 |
Ceribelli M, Kelly PN, Shaffer AL, Wright GW, Xiao W, Yang Y, Mathews Griner LA, Guha R, Shinn P, Keller JM, Liu D, Patel PR, Ferrer M, Joshi S, Nerle S, ... ... Thomas CJ, et al. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proceedings of the National Academy of Sciences of the United States of America. 111: 11365-70. PMID 25049379 DOI: 10.1073/Pnas.1411701111 |
0.376 |
|
| 2014 |
Vazquez-Ortiz G, Chisholm C, Xu X, Lahusen TJ, Li C, Sakamuru S, Huang R, Thomas CJ, Xia M, Deng C. Drug repurposing screen identifies lestaurtinib amplifies the ability of the poly (ADP-ribose) polymerase 1 inhibitor AG14361 to kill breast cancer associated gene-1 mutant and wild type breast cancer cells. Breast Cancer Research : Bcr. 16: R67. PMID 24962108 DOI: 10.1186/Bcr3682 |
0.312 |
|
| 2014 |
Onda M, Ghoreschi K, Steward-Tharp S, Thomas C, O'Shea JJ, Pastan IH, FitzGerald DJ. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. Journal of Immunology (Baltimore, Md. : 1950). 193: 48-55. PMID 24890727 DOI: 10.4049/Jimmunol.1400063 |
0.305 |
|
| 2014 |
Mathews Griner LA, Guha R, Shinn P, Young RM, Keller JM, Liu D, Goldlust IS, Yasgar A, McKnight C, Boxer MB, Duveau DY, Jiang JK, Michael S, Mierzwa T, Huang W, ... ... Thomas CJ, et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proceedings of the National Academy of Sciences of the United States of America. 111: 2349-54. PMID 24469833 DOI: 10.1073/Pnas.1311846111 |
0.386 |
|
| 2014 |
Duveau DY, Yasgar A, Wang Y, Hu X, Kouznetsova J, Brimacombe KR, Jadhav A, Simeonov A, Thomas CJ, Maloney DJ. Structure-activity relationship studies and biological characterization of human NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors. Bioorganic & Medicinal Chemistry Letters. 24: 630-5. PMID 24360556 DOI: 10.1016/J.Bmcl.2013.11.081 |
0.346 |
|
| 2014 |
Shukla S, Chufan EE, Singh S, Skoumbourdis AP, Kapoor K, Boxer MB, Duveau DY, Thomas CJ, Talele TT, Ambudkar SV. Abstract LB-224: Identification of a binding site for the tyrosine kinase inhibitor Nilotinib on the human ABC drug transporter, P-glycoprotein as determined by 3D-QSAR, molecular docking and mutational mapping Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-224 |
0.308 |
|
| 2014 |
Ali-Rahmani F, Fitzgerald D, Martin S, Patel P, Thomas C, Pastan I. Abstract 5428: Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) tyrosine kinase enhances cytotoxicity of anti-mesothelin immunotoxin Cancer Research. 74: 5428-5428. DOI: 10.1158/1538-7445.Am2014-5428 |
0.383 |
|
| 2014 |
Antignani A, Pasetto M, Choo C, Angelus E, Mathews L, Guha R, Shinn P, Ferrer M, Thomas CJ, Pastan I, Fitzgerald DJ. Abstract 2907: Everolimus enhances the cytotoxic action of the immunotoxin, HA22, directed to CD22 on B-cell malignancies Cancer Research. 74: 2907-2907. DOI: 10.1158/1538-7445.Am2014-2907 |
0.342 |
|
| 2013 |
Mathews LA, Keller JM, McKnight C, Michael S, Shinn P, Liu D, Staudt LM, Thomas CJ, Ferrer M. Multiplexing high-content flow (HCF) and quantitative high-throughput screening (qHTS) to identify compounds capable of decreasing cell viability, activating caspase 3/7, expressing annexin V, and changing mitochondrial membrane integrity. Current Protocols in Chemical Biology. 5: 195-212. PMID 24391083 DOI: 10.1002/9780470559277.Ch130060 |
0.307 |
|
| 2013 |
Rhyasen GW, Bolanos L, Fang J, Jerez A, Wunderlich M, Rigolino C, Mathews L, Ferrer M, Southall N, Guha R, Keller J, Thomas C, Beverly LJ, Cortelezzi A, Oliva EN, et al. Targeting IRAK1 as a therapeutic approach for myelodysplastic syndrome. Cancer Cell. 24: 90-104. PMID 23845443 DOI: 10.1016/J.Ccr.2013.05.006 |
0.35 |
|
| 2013 |
McDonnell SR, Hwang SR, Rolland D, Murga-Zamalloa C, Basrur V, Conlon KP, Fermin D, Wolfe T, Raskind A, Ruan C, Jiang JK, Thomas CJ, Hogaboam CM, Burant CF, Elenitoba-Johnson KS, et al. Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphoma. Blood. 122: 958-68. PMID 23814019 DOI: 10.1182/Blood-2013-01-482026 |
0.317 |
|
| 2013 |
Patel PR, Sun H, Li SQ, Shen M, Khan J, Thomas CJ, Davis MI. Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & Medicinal Chemistry Letters. 23: 4398-403. PMID 23787099 DOI: 10.1016/J.Bmcl.2013.05.072 |
0.385 |
|
| 2013 |
Coombs TC, Tanega C, Shen M, Wang JL, Auld DS, Gerritz SW, Schoenen FJ, Thomas CJ, Aubé J. Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315. Bioorganic & Medicinal Chemistry Letters. 23: 3654-61. PMID 23642479 DOI: 10.1016/J.Bmcl.2013.02.096 |
0.349 |
|
| 2013 |
Lin DC, Xu L, Ding LW, Sharma A, Liu LZ, Yang H, Tan P, Vadgama J, Karlan BY, Lester J, Urban N, Schummer M, Doan N, Said JW, Sun H, ... ... Thomas CJ, et al. Genomic and functional characterizations of phosphodiesterase subtype 4D in human cancers. Proceedings of the National Academy of Sciences of the United States of America. 110: 6109-14. PMID 23536305 DOI: 10.1073/Pnas.1218206110 |
0.35 |
|
| 2013 |
Casson L, Howell L, Mathews LA, Ferrer M, Southall N, Guha R, Keller JM, Thomas C, Siskind LJ, Beverly LJ. Inhibition of ceramide metabolism sensitizes human leukemia cells to inhibition of BCL2-like proteins. Plos One. 8: e54525. PMID 23342165 DOI: 10.1371/Journal.Pone.0054525 |
0.39 |
|
| 2013 |
Duveau DY, Hu X, Walsh MJ, Shukla S, Skoumbourdis AP, Boxer MB, Ambudkar SV, Shen M, Thomas CJ. Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors. Bioorganic & Medicinal Chemistry Letters. 23: 682-6. PMID 23273517 DOI: 10.1016/J.Bmcl.2012.11.111 |
0.338 |
|
| 2013 |
Casson L, Howell L, Mathews LA, Ferrer M, Southall N, Guha R, Keller JM, Thomas C, Siskind LJ, Beverly LJ. Inhibition of sphingosine kinase synergizes with ABT-263 to kill leukemia cells by causing accumulation of ceramide and sphingosine while decreasing glucosylceramide and S1P. Plos One. DOI: 10.1371/Journal.Pone.0054525.G005 |
0.303 |
|
| 2013 |
Lin D, Xu L, Ding L, Sharma A, Liu L, Yang H, Tan P, Vadgama J, Karlan B, Lester J, Urban N, Schummer M, Doan N, Said J, Walsh M, ... ... Thomas C, et al. Abstract 586: Genomic and functional characterizations of phosphodiesterase 4Din human cancers. Cancer Research. 73: 586-586. DOI: 10.1158/1538-7445.Am2013-586 |
0.337 |
|
| 2013 |
Miermont AM, Pflicke H, Guan H, Chinnasamy H, Thomas C, Rudloff U. Abstract 5538: Direct inhibition of ERK1/2 by VTX-11e leads to increased induction of apoptosis in a subset of pancreatic cancer cell lines as compared to MEK1/2 inhibition by selumetinib (AZD6244). Cancer Research. 73: 5538-5538. DOI: 10.1158/1538-7445.Am2013-5538 |
0.354 |
|
| 2013 |
Mathews LA, Guha R, Shinn P, Young RM, Lim K, Keller J, Liu D, Yasgar A, McKnight C, Boxer MB, Duveau DY, Jiang J, Michael S, Mott BT, Patel PR, ... ... Thomas CJ, et al. Abstract 4543: High-throughput combination screening identifies novel drug-drug pairings for a Bruton's tyrosine kinase inhibitor against the ABC subtype of diffuse large B-cell lymphomas. Cancer Research. 73: 4543-4543. DOI: 10.1158/1538-7445.Am2013-4543 |
0.386 |
|
| 2012 |
Dandapani S, Rosse G, Southall N, Salvino JM, Thomas CJ. Selecting, Acquiring, and Using Small Molecule Libraries for High-Throughput Screening. Current Protocols in Chemical Biology. 4: 177-191. PMID 26705509 DOI: 10.1002/9780470559277.Ch110252 |
0.307 |
|
| 2012 |
Johnson BC, Pauly GT, Rai G, Patel D, Bauman JD, Baker HL, Das K, Schneider JP, Maloney DJ, Arnold E, Thomas CJ, Hughes SH. A comparison of the ability of rilpivirine (TMC278) and selected analogues to inhibit clinically relevant HIV-1 reverse transcriptase mutants. Retrovirology. 9: 99. PMID 23217210 DOI: 10.1186/1742-4690-9-99 |
0.367 |
|
| 2012 |
Mott BT, Cheng KC, Guha R, Kommer VP, Williams DL, Vermeire JJ, Cappello M, Maloney DJ, Rai G, Jadhav A, Simeonov A, Inglese J, Posner GH, Thomas CJ. A furoxan-amodiaquine hybrid as a potential therapeutic for three parasitic diseases(). Medchemcomm. 3: 1505-1511. PMID 23205265 DOI: 10.1039/C2Md20238G |
0.309 |
|
| 2012 |
Mathews LA, Keller JM, Goodwin BL, Guha R, Shinn P, Mull R, Thomas CJ, de Kluyver RL, Sayers TJ, Ferrer M. A 1536-well quantitative high-throughput screen to identify compounds targeting cancer stem cells. Journal of Biomolecular Screening. 17: 1231-42. PMID 22927676 DOI: 10.1177/1087057112458152 |
0.365 |
|
| 2012 |
Anastasiou D, Yu Y, Israelsen WJ, Jiang JK, Boxer MB, Hong BS, Tempel W, Dimov S, Shen M, Jha A, Yang H, Mattaini KR, Metallo CM, Fiske BP, Courtney KD, ... ... Thomas CJ, et al. Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nature Chemical Biology. 8: 839-47. PMID 22922757 DOI: 10.1038/Nchembio.1060 |
0.352 |
|
| 2012 |
Treger RS, Cook AG, Rai G, Maloney DJ, Simeonov A, Jadhav A, Thomas CJ, Williams DL, Cappello M, Vermeire JJ. Oxadiazole 2-oxides are toxic to the human hookworm, Ancylostoma ceylanicum, however glutathione reductase is not the primary target. International Journal For Parasitology. Drugs and Drug Resistance. 2: 171-177. PMID 22844653 DOI: 10.1016/J.Ijpddr.2012.05.001 |
0.328 |
|
| 2012 |
Yang Y, Shaffer AL, Emre NC, Ceribelli M, Zhang M, Wright G, Xiao W, Powell J, Platig J, Kohlhammer H, Young RM, Zhao H, Yang Y, Xu W, Buggy JJ, ... ... Thomas C, et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell. 21: 723-37. PMID 22698399 DOI: 10.1016/J.Ccr.2012.05.024 |
0.316 |
|
| 2012 |
Heidebrecht RW, Mulrooney C, Austin CP, Barker RH, Beaudoin JA, Cheng KC, Comer E, Dandapani S, Dick J, Duvall JR, Ekland EH, Fidock DA, Fitzgerald ME, Foley M, Guha R, ... ... Thomas CJ, et al. Diversity-Oriented Synthesis Yields a Novel Lead for the Treatment of Malaria. Acs Medicinal Chemistry Letters. 3: 112-117. PMID 22328964 DOI: 10.1021/Ml200244K |
0.338 |
|
| 2012 |
McDonnell SR, Hwang SR, Basrur V, Conlon K, Fermin D, Murga-Zamalloa C, Rolland DCM, Thomas CJ, Elenitoba-Johnson KS, Lim MS. Phosphorylation of PKM2 by NPM-ALK Regulates a Metabolic Shift and Increased Oncogenic Potential Blood. 120: 896-896. DOI: 10.1182/Blood.V120.21.896.896 |
0.321 |
|
| 2011 |
Anastasiou D, Poulogiannis G, Asara JM, Boxer MB, Jiang JK, Shen M, Bellinger G, Sasaki AT, Locasale JW, Auld DS, Thomas CJ, Vander Heiden MG, Cantley LC. Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science (New York, N.Y.). 334: 1278-83. PMID 22052977 DOI: 10.1126/Science.1211485 |
0.31 |
|
| 2011 |
Walsh MJ, Brimacombe KR, Veith H, Bougie JM, Daniel T, Leister W, Cantley LC, Israelsen WJ, Vander Heiden MG, Shen M, Auld DS, Thomas CJ, Boxer MB. 2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorganic & Medicinal Chemistry Letters. 21: 6322-7. PMID 21958545 DOI: 10.1016/J.Bmcl.2011.08.114 |
0.33 |
|
| 2011 |
Shukla S, Skoumbourdis AP, Walsh MJ, Hartz AM, Fung KL, Wu CP, Gottesman MM, Bauer B, Thomas CJ, Ambudkar SV. Synthesis and characterization of a BODIPY conjugate of the BCR-ABL kinase inhibitor Tasigna (nilotinib): evidence for transport of Tasigna and its fluorescent derivative by ABC drug transporters. Molecular Pharmaceutics. 8: 1292-302. PMID 21630681 DOI: 10.1021/Mp2001022 |
0.335 |
|
| 2011 |
Chung S, Himmel DM, Jiang JK, Wojtak K, Bauman JD, Rausch JW, Wilson JA, Beutler JA, Thomas CJ, Arnold E, Le Grice SF. Synthesis, activity, and structural analysis of novel α-hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H. Journal of Medicinal Chemistry. 54: 4462-73. PMID 21568335 DOI: 10.1021/Jm2000757 |
0.305 |
|
| 2011 |
Rosenthal AS, Tanega C, Shen M, Mott BT, Bougie JM, Nguyen DT, Misteli T, Auld DS, Maloney DJ, Thomas CJ. Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk). Bioorganic & Medicinal Chemistry Letters. 21: 3152-8. PMID 21450467 DOI: 10.1016/J.Bmcl.2011.02.114 |
0.328 |
|
| 2011 |
Jiang JK, Shen M, Thomas CJ, Boxer MB. Chiral kinase inhibitors. Current Topics in Medicinal Chemistry. 11: 800-9. PMID 21291394 DOI: 10.2174/156802611795165052 |
0.343 |
|
| 2010 |
Rui L, Emre NC, Kruhlak MJ, Chung HJ, Steidl C, Slack G, Wright GW, Lenz G, Ngo VN, Shaffer AL, Xu W, Zhao H, Yang Y, Lamy L, Davis RE, ... ... Thomas CJ, et al. Cooperative epigenetic modulation by cancer amplicon genes. Cancer Cell. 18: 590-605. PMID 21156283 DOI: 10.1016/J.Ccr.2010.11.013 |
0.32 |
|
| 2010 |
Dolle RE, Bourdonnec BL, Worm K, Morales GA, Thomas CJ, Zhang W. Comprehensive survey of chemical libraries for drug discovery and chemical biology: 2009. Journal of Combinatorial Chemistry. 12: 765-806. PMID 20923157 DOI: 10.1021/Cc100128W |
0.31 |
|
| 2010 |
Jiang JK, Boxer MB, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW, Inglese J, Cantley LC, Auld DS, Thomas CJ. Evaluation of thieno[3,2-b]pyrrole[3,2-d]pyridazinones as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorganic & Medicinal Chemistry Letters. 20: 3387-93. PMID 20451379 DOI: 10.1016/J.Bmcl.2010.04.015 |
0.353 |
|
| 2010 |
Neumann S, Huang W, Eliseeva E, Titus S, Thomas CJ, Gershengorn MC. A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. Endocrinology. 151: 3454-9. PMID 20427476 DOI: 10.1210/En.2010-0199 |
0.347 |
|
| 2010 |
Boxer MB, Quinn AM, Shen M, Jadhav A, Leister W, Simeonov A, Auld DS, Thomas CJ. A highly potent and selective caspase 1 inhibitor that utilizes a key 3-cyanopropanoic acid moiety. Chemmedchem. 5: 730-8. PMID 20229566 DOI: 10.1002/Cmdc.200900531 |
0.327 |
|
| 2010 |
Auld DS, Lovell S, Thorne N, Lea WA, Maloney DJ, Shen M, Rai G, Battaile KP, Thomas CJ, Simeonov A, Hanzlik RP, Inglese J. Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proceedings of the National Academy of Sciences of the United States of America. 107: 4878-83. PMID 20194791 DOI: 10.1073/Pnas.0909141107 |
0.382 |
|
| 2010 |
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, Xu W, Shaffer AL, Wright G, Xiao W, Powell J, ... ... Thomas CJ, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 463: 88-92. PMID 20054396 DOI: 10.1038/Nature08638 |
0.307 |
|
| 2010 |
Boxer MB, Jiang JK, Vander Heiden MG, Shen M, Skoumbourdis AP, Southall N, Veith H, Leister W, Austin CP, Park HW, Inglese J, Cantley LC, Auld DS, Thomas CJ. Evaluation of substituted N,N'-diarylsulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Journal of Medicinal Chemistry. 53: 1048-55. PMID 20017496 DOI: 10.1021/Jm901577G |
0.361 |
|
| 2010 |
Mott BT, Ferreira RS, Simeonov A, Jadhav A, Ang KK, Leister W, Shen M, Silveira JT, Doyle PS, Arkin MR, McKerrow JH, Inglese J, Austin CP, Thomas CJ, Shoichet BK, et al. Identification and optimization of inhibitors of Trypanosomal cysteine proteases: cruzain, rhodesain, and TbCatB. Journal of Medicinal Chemistry. 53: 52-60. PMID 19908842 DOI: 10.1021/Jm901069A |
0.327 |
|
| 2010 |
Jadhav A, Ferreira RS, Klumpp C, Mott BT, Austin CP, Inglese J, Thomas CJ, Maloney DJ, Shoichet BK, Simeonov A. Quantitative analyses of aggregation, autofluorescence, and reactivity artifacts in a screen for inhibitors of a thiol protease. Journal of Medicinal Chemistry. 53: 37-51. PMID 19908840 DOI: 10.1021/Jm901070C |
0.328 |
|
| 2010 |
Santos JV, Vara A, Thomas C, Wangpaichitr M, You M, Savaraj N, Nguyen DM. Abstract 3489: Profound cytotoxicity of the histone deacetylase inhibitor SAHA (Suberoylanilide Hydroxamic Acid) and TRAIL (Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand) combination in malignant pleural mesothelioma Cancer Research. 70: 3489-3489. DOI: 10.1158/1538-7445.Am10-3489 |
0.333 |
|
| 2010 |
Shukla S, Skoumbourdis AP, Wu C, Hartz AMs, Bauer B, Thomas CJ, Ambudkar SV. Abstract 1535: Development of a fluorescent analog of BCR-ABL kinase inhibitor, Tasigna®(AMN-107, nilotinib) to study its interaction with ABC drug transporters Cancer Research. 70: 1535-1535. DOI: 10.1158/1538-7445.Am10-1535 |
0.351 |
|
| 2009 |
Mott BT, Tanega C, Shen M, Maloney DJ, Shinn P, Leister W, Marugan JJ, Inglese J, Austin CP, Misteli T, Auld DS, Thomas CJ. Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). Bioorganic & Medicinal Chemistry Letters. 19: 6700-5. PMID 19837585 DOI: 10.1016/J.Bmcl.2009.09.121 |
0.368 |
|
| 2009 |
Rai G, Thomas CJ, Leister W, Maloney DJ. Synthesis of Oxadiazole-2-oxide Analogues as Potential Antischistosomal Agents. Tetrahedron Letters. 50: 1710-1713. PMID 19802367 DOI: 10.1016/J.Tetlet.2009.01.120 |
0.308 |
|
| 2009 |
Rai G, Sayed AA, Lea WA, Luecke HF, Chakrapani H, Prast-Nielsen S, Jadhav A, Leister W, Shen M, Inglese J, Austin CP, Keefer L, Arnér ES, Simeonov A, Maloney DJ, ... ... Thomas CJ, et al. Structure mechanism insights and the role of nitric oxide donation guide the development of oxadiazole-2-oxides as therapeutic agents against schistosomiasis. Journal of Medicinal Chemistry. 52: 6474-83. PMID 19761212 DOI: 10.1021/Jm901021K |
0.309 |
|
| 2009 |
Fernandes AF, Bian Q, Jiang JK, Thomas CJ, Taylor A, Pereira P, Shang F. Proteasome inactivation promotes p38 mitogen-activated protein kinase-dependent phosphatidylinositol 3-kinase activation and increases interleukin-8 production in retinal pigment epithelial cells. Molecular Biology of the Cell. 20: 3690-9. PMID 19570915 DOI: 10.1091/Mbc.E08-10-1068 |
0.304 |
|
| 2009 |
Zhu PJ, Hobson JP, Southall N, Qiu C, Thomas CJ, Lu J, Inglese J, Zheng W, Leppla SH, Bugge TH, Austin CP, Liu S. Quantitative high-throughput screening identifies inhibitors of anthrax-induced cell death. Bioorganic & Medicinal Chemistry. 17: 5139-45. PMID 19540764 DOI: 10.1016/J.Bmc.2009.05.054 |
0.344 |
|
| 2009 |
Skoumbourdis AP, Leclair CA, Stefan E, Turjanski AG, Maguire W, Titus SA, Huang R, Auld DS, Inglese J, Austin CP, Michnick SW, Xia M, Thomas CJ. Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors. Bioorganic & Medicinal Chemistry Letters. 19: 3686-92. PMID 19464886 DOI: 10.1016/J.Bmcl.2009.01.057 |
0.353 |
|
| 2009 |
Auld DS, Zhang YQ, Southall NT, Rai G, Landsman M, MacLure J, Langevin D, Thomas CJ, Austin CP, Inglese J. A basis for reduced chemical library inhibition of firefly luciferase obtained from directed evolution. Journal of Medicinal Chemistry. 52: 1450-8. PMID 19215089 DOI: 10.1021/Jm8014525 |
0.319 |
|
| 2008 |
Jiang JK, Ghoreschi K, Deflorian F, Chen Z, Perreira M, Pesu M, Smith J, Nguyen DT, Liu EH, Leister W, Costanzi S, O'Shea JJ, Thomas CJ. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). Journal of Medicinal Chemistry. 51: 8012-8. PMID 19053756 DOI: 10.1021/Jm801142B |
0.32 |
|
| 2008 |
Neumann S, Kleinau G, Costanzi S, Moore S, Jiang JK, Raaka BM, Thomas CJ, Krause G, Gershengorn MC. A low-molecular-weight antagonist for the human thyrotropin receptor with therapeutic potential for hyperthyroidism. Endocrinology. 149: 5945-50. PMID 18669595 DOI: 10.1210/En.2008-0836 |
0.34 |
|
| 2008 |
Bhanu NV, Lee YT, Oneal PA, Gantt NM, Aerbajinai W, Noel P, Thomas CJ, Miller JL. Inhibition of erythroblast growth and fetal hemoglobin production by ribofuranose-substituted adenosine derivatives. Biochimica Et Biophysica Acta. 1782: 504-10. PMID 18586086 DOI: 10.1016/J.Bbadis.2008.05.004 |
0.333 |
|
| 2008 |
Engel S, Skoumbourdis AP, Childress J, Neumann S, Deschamps JR, Thomas CJ, Colson AO, Costanzi S, Gershengorn MC. A virtual screen for diverse ligands: Discovery of selective G protein-coupled receptor antagonists Journal of the American Chemical Society. 130: 5115-5123. PMID 18357984 DOI: 10.1021/Ja077620L |
0.313 |
|
| 2008 |
Sayed AA, Simeonov A, Thomas CJ, Inglese J, Austin CP, Williams DL. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nature Medicine. 14: 407-12. PMID 18345010 DOI: 10.1038/Nm1737 |
0.311 |
|
| 2008 |
Babaoglu K, Simeonov A, Irwin JJ, Nelson ME, Feng B, Thomas CJ, Cancian L, Costi MP, Maltby DA, Jadhav A, Inglese J, Austin CP, Shoichet BK. Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase. Journal of Medicinal Chemistry. 51: 2502-11. PMID 18333608 DOI: 10.1021/Jm701500E |
0.316 |
|
| 2008 |
Skoumbourdis AP, Huang R, Southall N, Leister W, Guo V, Cho MH, Inglese J, Nirenberg M, Austin CP, Xia M, Thomas CJ. Identification of a potent new chemotype for the selective inhibition of PDE4. Bioorganic & Medicinal Chemistry Letters. 18: 1297-303. PMID 18243697 DOI: 10.1016/J.Bmcl.2008.01.028 |
0.349 |
|
| 2008 |
Simeonov A, Jadhav A, Sayed AA, Wang Y, Nelson ME, Thomas CJ, Inglese J, Williams DL, Austin CP. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. Plos Neglected Tropical Diseases. 2: e127. PMID 18235848 DOI: 10.1371/Journal.Pntd.0000127 |
0.354 |
|
| 2008 |
Titus S, Neumann S, Zheng W, Southall N, Michael S, Klumpp C, Yasgar A, Shinn P, Thomas CJ, Inglese J, Gershengorn MC, Austin CP. Quantitative high-throughput screening using a live-cell cAMP assay identifies small-molecule agonists of the TSH receptor. Journal of Biomolecular Screening. 13: 120-7. PMID 18216391 DOI: 10.1177/1087057107313786 |
0.338 |
|
| 2008 |
Xie Y, Deng S, Thomas CJ, Liu Y, Zhang YQ, Rinderspacher A, Huang W, Gong G, Wyler M, Cayanis E, Aulner N, Többen U, Chung C, Pampou S, Southall N, et al. Identification of N-(quinolin-8-yl)benzenesulfonamides as agents capable of down-regulating NFkappaB activity within two separate high-throughput screens of NFkappaB activation. Bioorganic & Medicinal Chemistry Letters. 18: 329-35. PMID 18024113 DOI: 10.1016/J.Bmcl.2007.10.100 |
0.362 |
|
| 2007 |
Huang W, Zheng W, Urban DJ, Inglese J, Sidransky E, Austin CP, Thomas CJ. N4-phenyl modifications of N2-(2-hydroxyl)ethyl-6-(pyrrolidin-1-yl)-1,3,5-triazine-2,4-diamines enhance glucocerebrosidase inhibition by small molecules with potential as chemical chaperones for Gaucher disease. Bioorganic & Medicinal Chemistry Letters. 17: 5783-9. PMID 17827006 DOI: 10.1016/J.Bmcl.2007.08.050 |
0.332 |
|
| 2007 |
Ju W, Zhang M, Chen J, Thomas CJ, Waldmann TA. 67 The Drug CP690550 Inhibits the JAK3/STAT5 Pathway In Vitro and In Vivo Cytokine. 39: 19-19. DOI: 10.1016/J.Cyto.2007.07.072 |
0.315 |
|
| 2006 |
De Soto JA, Wang X, Tominaga Y, Wang RH, Cao L, Qiao W, Li C, Xu X, Skoumbourdis AP, Prindiville SA, Thomas CJ, Deng CX. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors. International Journal of Biological Sciences. 2: 179-85. PMID 16810332 DOI: 10.7150/Ijbs.2.179 |
0.32 |
|
| 2005 |
Besada P, Mamedova L, Thomas CJ, Costanzi S, Jacobson KA. Design and synthesis of new bicyclic diketopiperazines as scaffolds for receptor probes of structurally diverse functionality. Organic & Biomolecular Chemistry. 3: 2016-25. PMID 15889186 DOI: 10.1039/B416349D |
0.317 |
|
| 2003 |
Wolak MA, Thomas CJ, Gillespie NB, Birge RR, Lees WJ. Tuning the optical properties of fluorinated indolylfulgimides. The Journal of Organic Chemistry. 68: 319-26. PMID 12530855 DOI: 10.1021/Jo026374N |
0.737 |
|
| 2002 |
Wolak MA, Finn RC, Rarig RS, Thomas CJ, Hammond RP, Birge RR, Zubieta J, Lees WJ. Structural properties of a series of photochromic fluorinated indolylfulgides. Acta Crystallographica. Section C, Crystal Structure Communications. 58: o389-93. PMID 12094055 DOI: 10.1107/S0108270102008041 |
0.725 |
|
| 2001 |
Wolak MA, Sullivan JM, Thomas CJ, Finn RC, Birge RR, Lees WJ. Thermolysis of a fluorinated indolylfulgide features a novel 1,5-indolyl shift. The Journal of Organic Chemistry. 66: 4739-41. PMID 11421804 DOI: 10.1021/Jo015693W |
0.59 |
|
| 2001 |
Thomas CJ, Wolak MA, Birge RR, Lees WJ. Improved synthesis of indolyl fulgides. The Journal of Organic Chemistry. 66: 1914-8. PMID 11262147 DOI: 10.1021/Jo005722N |
0.727 |
|
| Show low-probability matches. |